VolitionRx (VNRX) said Thursday it has extended its Nu.Q Vet Cancer Test supply deal with Fujifilm Vet Systems in Japan for a new five-year initial term to include the chemiluminescent immunoassay version of the test through an automated analyzer platform.
The agreement previously allowed Fujifilm to provide the test to Japanese veterinarians in a manual format, VolitionRx said.
Fujifilm will work with VolitionRx for the final validation and verification of the automated platform for canine cancer screening for a launch in the summer, according to VolitionRx.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.